Stay informed by listening to a podcast of our April teleconference, Triple-Negative Breast Cancer: Genetic Risk and Treatment Updates.
Distinguished professor of oncology Rebecca Dent, MSc, MD, FRCP(C), of the University of Toronto and Sunnybrook Odette Cancer Centre, explains the latest research studies related to triple-negative breast cancer. She also describes the current treatments available for this diagnosis. Prominent professor of surgery Lisa A. Newman, MD, MPH, FACS of the University of Michigan in Ann Arbor, discusses various risk factors for triple-negative breast cancer, including gene mutation, age, race and ethnicity. She offers suggestions of ways to possibly reduce your risk for recurrence by making lifestyle changes.
About Our Speakers
Dr. Dent is a nationally recognized expert in triple-negative breast cancer treatment and research. She is an assistant professor of medical oncology at the University of Toronto. Dr. Dent heads breast cancer clinical trials at the Sunnybrook Odette Cancer Centre in Toronto, where she serves as chair of the locally advanced breast cancer program. She also sits on the breast cancer new drug development committee for the National Cancer Institute of Canada. Dr. Dent is the principal investigator for clinical trials for the treatment of advanced breast cancer, including the role of PARP inhibitors in triple-negative disease.
Dr. Newman is a professor of surgery and director of the breast care center for the University of Michigan in Ann Arbor, Michigan, where she also serves as program director for the breast fellowship. She holds leadership positions with the Society of Surgical Oncology and the American Society of Clinical Oncology. Dr. Newman serves on the breast prevention section of the National Comprehensive Cancer Network. She is the chief national medical advisor for Sisters Network, Inc., a national African-American breast cancer support organization.
About the Program